Nektar Therapeutics Finalizes Terms for $150M At-The-Market Offering
NKTR has more than doubled off its 52-week low of $7.99.
Summary
Nektar Therapeutics filed a prospectus supplement to finalize the terms of its previously announced At-The-Market (ATM) equity offering, allowing it to sell up to $150 million in common stock.
Key Events · Financing and Capital Events · NKTR
-
Finalizes $150 Million At-The-Market Offering
Nektar Therapeutics has filed a prospectus supplement to establish an At-The-Market (ATM) equity offering program, enabling the company to sell up to $150,000,000 of its common stock from time to time through sales agents Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC. This filing operationalizes the program announced in a concurrent 8-K filing.
-
Capital for R&D and Clinical Development
The net proceeds from this offering are intended for general corporate purposes, including funding research and development, clinical development costs (specifically mentioning Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing to advance its drug candidates.
-
Potential Share Dilution
The offering, if fully utilized, could result in the issuance of approximately 1,762,839 shares based on a recent market price, representing potential dilution to existing shareholders. The filing notes an immediate dilution of $54.51 per share to new investors at an assumed offering price of $85.09 per share.
Analysis · NKTR · Life Sciences
This 424B5 prospectus supplement provides the full legal framework and detailed terms for the At-The-Market (ATM) equity offering program, which was initially announced via an 8-K filing on May 8, 2026. The offering allows Nektar to sell up to $150 million of common stock from time to time through sales agents. While dilutive, this program is crucial for a clinical-stage biopharmaceutical company like Nektar to secure capital for general corporate purposes, including funding ongoing research and development, clinical trials (such as Phase 3 trials for rezpegaldesleukin), and manufacturing costs. The ability to access capital is vital for extending the company's operational runway, especially following its recent Q1 earnings report which showed a narrowed net loss and increased cash reserves. Investors should monitor the pace and pricing of future sales under this program.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 29% of the 1653 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NKTR was trading at $82.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $7.99 to $109.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.